



Working to improve your health

24 JULY 2026

Pitt St Research initiates coverage on AFT Pharmaceuticals

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that Pitt St Research has initiated coverage on AFT Pharmaceuticals Ltd.

Pitt St is an Australian based research organisation providing issuer-sponsored equity research on ASX-listed life sciences companies since 2016.

The report is available on the AFT Pharmaceuticals website at [Pitt St Research initiates coverage on AFT Pharmaceuticals – AFT Pharmaceuticals](#)

The views contained in the report are the views of Pitt St Research.

Released for, and on behalf of, AFT Pharmaceuticals Limited by Stuart Houliston, Chief Financial Officer.

For more information:

Investors

Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media

Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription, and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs¹. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland, and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.